Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Yuichiro SuzukiShinya MaekawaKohji YamashitaLeona OsawaYasuyuki KomiyamaNatsuko NakakukiHitomi TakadaMasaru MuraokaMitsuaki SatoShinichi TakanoMitsuharu FukasawaTatsuya YamaguchiSatoshi FunayamaHiroyuki MorisakaHiroshi OnishiNobuyuki EnomotoPublished in: Journal of gastroenterology and hepatology (2023)
Combined treatment with pemafibrate and a low-carbohydrate diet resulted in weight loss and improvements in ALT, MRE, and MRI-PDFF in MAFLD patients. Although such improvements were associated with weight loss in obese patients, the improvements were observed irrespective of weight loss in non-obese patients, indicating this combination can be effective both in obese and non-obese MAFLD patients.
Keyphrases
- weight loss
- bariatric surgery
- obese patients
- roux en y gastric bypass
- gastric bypass
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- adipose tissue
- type diabetes
- physical activity
- prognostic factors
- metabolic syndrome
- weight gain
- body mass index
- magnetic resonance
- insulin resistance
- skeletal muscle